The Oncology journal: Oncotarget Improves Access To The Latest Findings

Oncotarget is a peer-reviewed multidisciplinary journal that was launched in 2010 by scientists working in cancer research and other areas of oncology biology. It is an open access journal to help in the dissemination of oncology research results to large numbers of people and researchers around the world. Oncotarget aims at making scientific research on cancer widely available. However, the journal also publishes a lot of findings other topics such as aging, immunology, microbiology, and pathology. Download output styles at

Cancer has become a serious public health concern, and it is encouraging that Oncotarget has focused its energies on making oncology findings available to those involved in the frontline war against this stubborn disease. Oncotarget makes bi-weekly publications to ensure that there is a constant flow of information. This is how it contributes to scientific progress in oncology; by publishing work of some of the leading lights in the field. The journal intends to make scientific evidence easy to share. Oncotarget brings together various experts in multiple oncology fields to expand the number of topics covered in the journal. Watch this video on Youtube.

The journal has had an enormous impact since inception. It has a broad reach of about ten thousand cities to date. This has turned it into one of the most reliable and accessible medical journals for oncology. It has been indexed by Biosis previews, Scopus and Index Medicus. It is an excellent success and can be credited to high editorial standards set by the editors. Oncotarget has some of the most distinguished scientists and researchers for editors including notable Nobel prize winners.

Oncotarget also promotes the application of its research to future scientific inquiry. That is why it sponsors medical conferences around the world. The Gordon research conference recently held in Italy is one example. That discussed everything ranging from stem cell aging, progression to cancer initiation. At the Frontiers in Cancer Science Conference, Oncotarget proudly sponsored the work of several scientists working on cutting edge treatments for cancer. Multiple scholars received accolades and distinguished honors for their work in the field of oncology. By creating an environment for scientific exchange Oncotarget has furthered the way that oncology is discussed and research is propagated.

Learn more:

Dr. Clay Siegall’s Achievements as the Co-Founder of Seattle Genetics

Dr. Clay Siegall serves as the CEO of Seattle Genetics, a Seattle-based biotechnology company that he founded. The firm develops targeted therapy drugs that are meant for the disease types known not to have had considerable mortality improvements in the recent decades. From the University of Maryland, Dr. Siegall acquired a B.S. in Zoology and from George Washington University he holds a Ph.D. in genetics. Seattle Genetics has become a major power player in cancer research under Siegall’s leadership.

His inspiration to come up with Seattle Genetics was the interest that he has in medicine, the reason to fight diseases and the power of technology. In all these, he wanted to avert the fate of those who were facing death. Dr. Clay Siegall first developed an interest in the treatment of cancer while at the University of Maryland undertaking his studies in Zoology. He was also inspired by the quest for money to start up the venture.

At Seattle Genetics, making money is done in different ways. The first way is by selling their proprietary drugs. The revenues are also generated from production partnerships. Licensing of processes and technologies that they have developed also earns them great amounts of money. The firm has a dynamite of sales personnel that steer the business forward. In his words, Dr. Siegall asserts that it is hard work that makes him successful.

About Clay Siegall

Clay B. Siegall the CEO, the President as well as the Chairperson of the Board of Seattle Genetics, a firm that he co-founded in 1998. He built the company with the emphasis on rigorous research, drug development practices, scientific innovation and the passion for helping patients. Dr. Siegall has since steered the company to its current leadership position with tremendous achievements in targeted cancer therapy.

Between 1991 and 1997, he worked at the Bristol-Myers Squibb Pharmaceutical Research Institute after working with National Cancer Institute, National Institutes of Health between 1988 and 1991. Dr. Siegall is a Ph.D. holder in the field of genetics from George Washington University. He also has B.S. in Zoology that he holds from the University of Maryland.